Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus chidamide in T/NK-cell lymphoma (ChiCTR2000037232)
ChiCTR2000037232Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azacitidine and tucidinostat in T/NK-cell lymphoma (ENKTCL) and T-cell and natural killer cell lymphoma, sponsored by Anhui Provincial Tumor Hospital. Primary endpoints: Progression-free survival at 1 year in elderly newly diagnosed patients and Best objective response rate in relapsed patients. Started Aug 2020; status: recruiting.
02
Drugs
azacitidinetucidinostat
03
Conditions
T/NK-cell lymphoma (ENKTCL)T-cell and natural killer cell lymphoma
Beyond the preview
Go deeper on ChiCTR2000037232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037232.